Results 111 to 120 of about 66,270 (188)
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Electron microscopy reveals microstructural alterations in cardiomyocyte nuclei and myofilaments in non‐ischaemic cardiomyopathy (NICM), particularly in dilated cardiomyopathy (DCM). Nevertheless, the correlation between such observations and clinical outcomes, including prognosis and left ventricular reverse remodelling (LVRR), remains ...
Rie Higuchi +19 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims The study aims to investigate the impact of immigration status on short‐ and long‐term outcomes in patients hospitalized with acute decompensated heart failure (ADHF). Methods We conducted a retrospective cohort study at a single centre, analysing 7457 patients admitted for ADHF between 2007 and 2017, with follow‐up until 2020 (mean 3.7 ±
Gil Marcus +9 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abbreviations: TAVI, transcatheter aortic valve implantation; ATTR‐CM, transthyretin cardiac amyloidosis. We aimed to diagnose occult ATTR‐CM in patients with severe aortic stenosis undergoing TAVI using bone scintigraphy. We verified a diagnosis of ATTR‐CM in 8 of 171 (4.7 %) consecutive aortic stenosis patients who underwent TAVI.
Margrethe Flesvig Holt +15 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Information about current use of finerenone in patients with heart failure (HF) finerenone in clinical practice is scarce, and its effectiveness in clinical practice in patients is scarce. We aim to assess both the baseline clinical profile and prognostic role of finerenone in patients with HF, irrespective of ejection fraction.
Gonzalo Luis Alonso Salinas +32 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new‐onset atrial fibrillation in patients with heart failure using linked real‐world UK data from primary and secondary care, along with findings from genome‐wide association studies. Methods and results Among 163 174 participants
Hiroyuki Yoshimura +6 more
wiley +1 more source
ESC Heart Failure, EarlyView.Asymptomatic reduced left ventricular ejection fraction (LVEF) in the acute phase of myocardial infarction (AMI) was associated with up to 20% 1‐year mortality after discharge, substantially higher than in recent post‐MI trials. Symptoms of heart failure (HF) during the index hospitalization was associated with worse outcomes in patients with preserved
Jarle Jortveit +3 more
wiley +1 more source
ESC Heart Failure, EarlyView.The H2‐Registry: overview, first results and outlook. Abstract Aims Heart failure (HF) is a highly prevalent condition affecting 1–3% of the adult population in Europe. Despite landmark improvements in HF care over the last two decades, hospitalization and mortality rates remain relatively high.
Johannes Leiner +15 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Inter‐atrial shunt device therapy has shown mixed results in clinical trials, with clinical ‘non‐responders’ typically showing features of more advanced heart failure. We aimed to analyse the haemodynamic and clinical response of a novel left atrial to coronary sinus (LA‐CS) shunt device in patients with higher natriuretic peptide (NP ...
Ryan J. Tedford +9 more
wiley +1 more source
Congestion, decongestion, renal function and diuretics in (ESC) heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus +2 more
wiley +1 more source